Little Green Pharma Ltd (ASX:LGP) finished the latest trading session with a 4.55% gain, closing at AUD 0.115. Trading turnover reached AUD 57,328, while the company maintained a market capitalisation of approximately AUD 28.89 million. Although the stock has declined 22.03% over the past year, the latest advance renewed market attention as the company continues…
Browsing: Pharma
India’s Sun Pharmaceutical Industries has received approval from South Africa’s health regulator to manufacture and sell a generic version of semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, expanding its presence in the fast-growing GLP-1 market.
New Delhi:Sun Pharmaceutical Industries Limited has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
The product will be offered as a pre-filled, multi-dose injectable pen in two strengths—2 mg/1.5 mL and 4 mg/3 mL—enabling flexible once-weekly dosing
Sun Pharmaceutical Industries Ltd. on Wednesday (July 15, 2026) said it has received approval from the South African regulator to manufacture and market a generic version of semaglutide injection in the country for treatment of adults with type 2 diabetes mellitus.
Revital, Sun Pharma’s flagship multivitamin brand, has launched a new integrated campaign featuring Bollywood actor Vicky Kaushal, betting on a broader conversation around energy, stress and modern lifestyles rather than traditional messaging centred on physical tiredness. Viswanath Pilla July 15, 2026 / 20:43 IST Sun Pharma
New Delhi, July 15: India-origin pharmaceutical patent families have risen more than four-fold over the past decade, while the country’s drug discovery pipeline has expanded to more than 1,095 programmes across 195 companies, signalling a rapid shift from generics-led manufacturing to innovation-driven research, a report showed on Wednesday.
Sun Pharma has secured approval from South Africa’s SAHPRA to manufacture and market a generic semaglutide injection, making South Africa the second market after India to grant such approval. The product will be launched as a pre-filled, multi-dose injectable pen in two strengths — 2 mg/1.5 mL and 4 mg/3 mL — with once-weekly dosing…
Market snapshot: Sun Pharmaceutical Industries Limited has obtained regulatory approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa, expanding its global footprint in the metabolic and diabetes therapy segment (Source: NSE India, 15 Jul 2026, https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFhYeBDvjMV-vCkAASidsCo5XFAIUZFtauU92vnQAvq3hkAtULKTI_eJjjb26gLaOCZkymJD7e-On0gl9Kt3qx8DHXAsH5dC8n2-5zTthk8RY2ekI_JaCOvtAKyPzxnDg0KsHE9D86bcUopAxkhmS5pEHjeRBzaCjwsDks8aTgB5ysfnLHhVLKRbq2X8SNpyenzJ-mcxFN7evYoT1b2ulY-). This marks the second market…
In recent health updates, a German hospital is treating a US citizen who contracted Ebola in the Democratic Republic of Congo. The patient was admitted to Frankfurt University Hospital’s specialized isolation unit.